findmyKOL

Peter Ruane, MD

Enriched profile

Medical Director and Founder, Ruane Clinical Research · Ruane Clinical Research

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Los Angeles, CA · West · United StatesSpecialtyInfectious DiseaseFocusHIV
Active KOLfindmyKOL type: EliteLatest publication2019Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Peter Ruane is Medical Director and Founder, Ruane Clinical Research at Ruane Clinical Research. OpenAlex indexes 139 publications with 13,845 citations (h-index 51); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Infectious Disease profiles in the findmyKOL directory.

Data verified 25 Aug 2026

Overview

Updated 14 Oct 2026

Peter Ruane, MD, is Medical Director and Founder, Ruane Clinical Research. The public record shows 139 publications with 13,845 citations (h-index 51), centered on HIV. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 36 companies.

  • Most recent indexed publication: 2019 · Journal of viral hepatitis
  • Top research focus: HIV
  • 3 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 36 companies

Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
HIV2 trialsHIV Infections2 trialsViral Hepatitis (B/C)1 trialHepatitis C1 trialHepatitis C, Chronic1 trialHepatitis, Chronic1 trial

Research focus

OpenAlex concept fingerprint
HIV

Drugs & molecules

across trials, industry payments and publications
Dovatogeneric · Dolutegravir / lamivudineClinical trials—Industry payments111Publications—CabenuvaClinical trials—Industry payments82Publications—Apretudegeneric · CabotegravirClinical trials—Industry payments48Publications—Mytesigeneric · CrofelemerClinical trials—Industry payments34Publications—Repathageneric · EvolocumabClinical trials—Industry payments29Publications—Symtuzageneric · Cobicistat / darunavir / emtricitabine / tenofovir alafenamideClinical trials—Industry payments29Publications—Otezlageneric · ApremilastClinical trials—Industry payments27Publications—Pifeltrogeneric · DoravirineClinical trials—Industry payments20Publications—Aplenzingeneric · BupropionClinical trials—Industry payments17Publications—Rukobiageneric · FostemsavirClinical trials—Industry payments16Publications—Delstrigogeneric · Doravirine / lamivudine / tenofovir disoproxilClinical trials—Industry payments13Publications—Xyostedgeneric · TestosteroneClinical trials—Industry payments11Publications—

Works with

trial sponsors and companies reporting payments
ViiV Healthcare CompanyClinical trials—Industry payments270Gilead Sciences, Inc.Clinical trials—Industry payments75Napo Pharmaceuticals IncClinical trials—Industry payments34Amgen Inc.Clinical trials—Industry payments30Janssen Biotech, Inc.Clinical trials—Industry payments28EMD Serono, Inc.Clinical trials—Industry payments25Merck Sharp & Dohme LLCClinical trials—Industry payments21Bausch Health US, LLCClinical trials—Industry payments16Salix Pharmaceuticals, a division of Bausch Health US, LLCClinical trials—Industry payments12AstraZeneca Pharmaceuticals LPClinical trials—Industry payments10Lilly USA, LLCClinical trials—Industry payments9Abbvie Inc.Clinical trials—Industry payments6GlaxoSmithKline, LLC.Clinical trials—Industry payments6Merck Sharp & Dohme CorporationClinical trials—Industry payments6Antares Pharma, Inc.Clinical trials—Industry payments5Novo Nordisk IncClinical trials—Industry payments5Theratechnologies Inc.Clinical trials—Industry payments5Nestle HealthCare Nutrition Inc.Clinical trials—Industry payments4Amarin Pharma Inc.Clinical trials—Industry payments3Axsome Therapeutics, Inc.Clinical trials—Industry payments3Eisai Inc.Clinical trials—Industry payments3ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)Clinical trials—Industry payments3Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments3Melinta Therapeutics, LLCClinical trials—Industry payments2Pfizer Inc.Clinical trials—Industry payments2Acerus Pharmaceuticals CorporationClinical trials—Industry payments1Clarus Therapeutics Inc.Clinical trials—Industry payments1Corcept TherapeuticsClinical trials—Industry payments1Dynavax Technologies CorporationClinical trials—Industry payments1Hologic, LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
139publications

Distinct works indexed by OpenAlex, matched via ORCID; 1 in PubMed.

13,845citations

Total citations across indexed works.

51h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
3clinical trials

Investigator role on registered studies.

View trials ↓
36companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 14 Oct 2026

Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 14 Oct 2026

36 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    46.4%
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor13.4%
    Descovy83%Triumeq17%
    Part D<11 patients
    Protease Inhibitor10%
    Prezcobix51%Symtuza31%Prezista17%
    Part D<11 patients

    + 5 more classes in this area

  • Cardiovascular

    19.4%
    Statin8.4%
    Rosuvastatin Calcium56%Atorvastatin Calcium44%
    Part D<11 patients
    Angiotensin receptor blocker (ARB)6%
    Losartan Potassium57%Olmesartan Medoxomil43%
    Part D<11 patients

    + 3 more classes in this area

  • Nervous system

    9.1%
    Gabapentinoids6%
    Gabapentin100%
    Part D≥11 patients
    SSRI3.1%
    Trazodone Hcl100%
    Part D<11 patients
All 9 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 14 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 14 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • LinkedIn

    linkedin.com/company/ruane-clinical-research

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • Other

    croiwebcasts.org/p/2020croi/croi/39

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →croiwebcasts.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 14 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University College Dublin

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com ↗
  • Internal Medicine Residency

    Mayo Clinic (Rochester, MN)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com ↗
  • Research and Clinical Fellowship in Infectious Diseases

    West Los Angeles Veterans Affairs Medical Center

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com ↗
  • Board Certified

    Infectious Diseases

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →suite401.com ↗

Editorial & leadership roles

journal and society appointments

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Speaker/presenter

    "Therapeutic Interventions for HIV Treatment and Eradication" session, CROI 2020 (Conference on Retroviruses and Opportunistic Infections) webcast

    2020
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →croiwebcasts.org ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.